New HIV Drugs in Development, 2005. (Q36104947)

12 August 2017

title

New HIV Drugs in Development, 2005. (English)

1 reference

12 August 2017

Jeffrey P Nadler

1

1 reference

12 August 2017

Michael C Phillips

series ordinal

2

1 reference

12 August 2017

publication date

1 May 2005

1 reference

Current infectious disease reports

12 August 2017

published in

1 reference

12 August 2017

volume

7

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

221-226

1 reference

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

12 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11908-005-0038-5

CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11908-005-0038-5

Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms.

21 January 2018

1 reference

12 December 2020

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

12 December 2020

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

12 December 2020

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations

1 reference

12 December 2020

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.

1 reference

12 December 2020

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

1 reference

12 December 2020

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples

1 reference

12 December 2020

HIV-1 protease inhibitors. A review for clinicians

1 reference

12 December 2020

An introduction to nucleoside and nucleotide analogues.

1 reference

12 December 2020

Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors

1 reference

12 December 2020

"Buffalo hump" in men with HIV-1 infection.

1 reference

12 December 2020

Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo

1 reference

12 December 2020

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

12 December 2020

Spectrum of antiviral activity and mechanism of action of zidovudine. An overview

1 reference

12 December 2020

HIV-protease inhibitors

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study

1 reference

12 December 2020

Biochemical mechanisms involved in overcoming HIV resistance to nucleoside inhibitors of reverse transcriptase

1 reference

12 December 2020

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

1 reference

12 December 2020

Tipranavir: A Protease Inhibitor From a New Class With Distinct Antiviral Activity

1 reference

12 December 2020

10.1007/S11908-005-0038-5

Identifiers

DOI

1 reference

12 August 2017

1 reference